Holiday Office Closure
Happy Holidays from Texas Retina! Our offices will be closed Tuesday, December 24, 2024, and Wednesday, December 25, 2024. We wish you and your family health and happiness this holiday season!
read more
Dr. Abbey Reports on New Method to Measure Retinal Fluid After Treatment with Faricimab for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored an article in the medical journal Eye on the use of a novel deep-learning algorithm to quantify retinal fluid changes in patients treated with
read more
Dr. Kothari Featured in New Retina Radio Podcast
Texas Retina’s Nikisha Kothari, MD, recently participated in a new podcast released by the New Retina Radio Journal Club and Vit-Buckle Society. In it, she discusses research published earlier this year in
read more
Dr. Coors Treats First Patient in DAYBREAK Clinical Trial of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer for Wet AMD
Texas Retina’s Lori E. Coors, MD, recently enrolled and treated the first patient in the Phase III DAYBREAK trial evaluating an intravitreal tarcocimab tedromer and tabirafusp tedromer compared with intravitreal aflibercept in
read more
Dr. Abbey Presented at the Outpatient Ophthalmic Surgery Society (OOSS) Symposium 2024
Texas Retina’s Ashkan Abbey, MD, recently presented “Innovation in Retina for the ASC” at the Outpatient Ophthalmic Surgery Society (OOSS) Symposium 2024. He highlighted the advantages and disadvantages of several recent surgical
read more
Texas Retina’s New Wichita Falls Office Opening November 7!
We’re excited to announce that our new, larger Wichita Falls office will officially open on November 7, 2024! This new office will replace our current Wichita Falls office and at 7,500 square
read more
Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Dr. Abbey Taught a Course at the American Academy of Ophthalmology 2024 Annual Meeting
For the fifth year, Texas Retina’s Ashkan M. Abbey, MD, taught a continuing medical education (CME) course titled, “Secondary IOL Techniques for Retinal Specialists,” at the annual meeting of the American Academy
read more
Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more
Dr. Abbey Presented 2.5 Year Results of the TRUCKEE Study at The Retina Society Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study – 2.5 Year Results” at the 57thAnnual Scientific Meeting of
read more